Efficacy and Safety of Chiglitazar vs. Sitagliptin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Noninferiority Phase 3 Trial (CMAS)

This article has no abstract
Epistemonikos ID: 29bc6a46c73be495cf5803842516dadd330f8b54
First added on: Feb 11, 2025